Quinsair (levofloxacin)
- Region
- 🇪🇺 EU
- Active substance
- levofloxacin
- Company
- Chiesi Farmaceutici S.p.A
- Status
- Authorised
- Therapeutic area
- Cystic Fibrosis; Respiratory Tract Infections
- CHMP opinion
- Thu 18 Dec 2014
- EU approval
- Wed 25 Mar 2015
- Application
- EMEA/H/C/002789
- ATC
- J01MA12
- Official record
- www.ema.europa.eu
Indication
Quinsair is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Regulatory milestones
No milestones recorded in the last year.
Follow Quinsair
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.